Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
presentation. We plan to let candidates know if they have progressed to the selection stage in early July 2025. If you need any support, equipment or adjustments to enable you to participate in any element of
-
, offering seamless functionality and enhanced performance. However, the material incompatibility between flexible, soft bioelectronics and hard, rigid electronic components poses a significant barrier
-
accepted all year round Details The tumour microenvironment (TME) plays a pivotal role in controlling cancer progression and response to therapy. A key component of the TME is the extracellular matrix (ECM
-
and fluid transport. However, we still don’t fully understand how seemingly independent components, like neurons, glial cells, and vascular structures, work together to achieve optimal tissue coverage
-
fingerprints for damage hidden in the data. Project Description: In nuclear fusion reactors, particularly plasma-facing first wall components and breeder blanket modules, materials are subjected to extreme
-
9th June 2025. If you need any support, equipment or adjustments to enable you to participate in any element of the recruitment process you can contact: saas-business-support@sheffield.ac.uk We
-
/ interview) Ability to work to clear timescales, progressing several tasks at one time whilst maintaining accuracy (assessed at application / interview) Confident in working independently and as part of a
-
September 2025. If appointed, you would play an important part in our team and contribute to research-led teaching. We are especially keen to attract applicants able to teach in one or more of the following
-
window). We are a Disability Confident Employer. If you have a disability and meet the essential criteria for this job you will be invited to take part in the next stage of the selection process.
-
technology, and cross-care pathways. IT Project Management: Manage additional IT projects related to or as part of the E-IMMUNE programme (such as the proposed National Late Effects Immunotherapy Database